Eli Lilly's Regulatory Streak and Pipeline Pruning Keep Wall Street Bulls in Command
Published on 10/02/2026 at 14:32 | Editorial boerse-global.de
A wave of FDA approvals across diabetes, oncology and immunology has reinforced Eli Lilly's standing in the pharmaceutical sector, even as the company moves decisively to cull a stalled early-stage program and redirect resources toward its most promising candidates.
The Indianapolis-based drugmaker's shares closed Tuesday at EUR 1,023.40, a marginal dip of 0.04%, leaving the equity essentially flat as investors digested a mix of pipeline setbacks and regulatory wins. Since the start of the year, the stock has climbed 12%.
Fresh Approvals Across Three Therapeutic Areas
Within a matter of days, Lilly secured several key green lights from US regulators. The FDA granted marketing authorization for Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type-2 diabetes, which is slated to reach the American market in the coming months. The agency also broadened the label for Olumiant (baricitinib), now cleared for pediatric patients aged twelve and older suffering from severe alopecia areata.
Those decisions followed the full approval, granted on 18 September, of the combination of Inluriyo (imlunestrant) and Verzenio (abemaciclib) for adults with advanced or metastatic breast cancer carrying specific genetic mutations after prior endocrine therapy. Together, the new market entries bolster Lilly's core franchises beyond its headline-grabbing weight-loss treatments, adding fresh revenue streams in diabetes and oncology.
Should investors sell immediately? Or is it worth buying Eli Lilly?
EloraTZP Delivers Head-Turning Phase 2b Data
Lilly is keeping its foot on the gas in clinical research as well. A phase 2b trial involving 367 adults tested the candidate EloraTZP in patients with obesity or overweight plus type-2 diabetes. Over 48 weeks, participants achieved average weight loss of up to 23.3% (54.1 pounds), while the comparator arm receiving tirzepatide 15 mg recorded a decline of 14.8% (34.4 pounds). Blood sugar marker A1C fell by as much as 2.9 percentage points versus 2.4 points under tirzepatide. Lilly has said it will kick off phase 3 studies in the fourth quarter of 2026.
Not every program has fared as well. Working alongside Foghorn Therapeutics, Lilly halted development of FHD-909 after reviewing phase-1 dose-escalation data. According to Foghorn, the molecule proved generally safe but failed to demonstrate sufficient efficacy to justify advancing into the clinical expansion phase. Such selection decisions are routine for research-driven pharmaceutical companies seeking to concentrate resources on candidates with a higher probability of success.
New Partnerships and Manufacturing Muscle
Lilly is simultaneously expanding its external network. On 24 September, the company struck a research and licensing collaboration with InnoCare Pharma to develop new active substances. InnoCare stands to receive up to USD 100 million in upfront and near-term payments, plus potential milestone payments of roughly USD 3.25 billion.
On the industrial side, the group broke ground in Houston on a USD 6.5 billion production facility for pharmaceutical active ingredients, expected to create more than 600 jobs.
Analysts Stay Bullish
Confidence on Wall Street remains intact despite isolated pipeline disappointments. Evan Seigerman of BMO Capital reaffirmed his "Outperform" rating with a USD 1,400 price target. Chris Schott of JPMorgan had already lifted his target from USD 1,400 to USD 1,500 on 28 September while maintaining an "Overweight" stance, citing continued strength in incretin products both in the US and on international markets.
Investors will get a fuller picture of the business trajectory in just a few weeks: Lilly has scheduled its third-quarter 2026 earnings call for 29 October.
Ad
Eli Lilly Stock: New Analysis - 2 October
Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
